{"hands_on_practices": [{"introduction": "Effective screening for pheochromocytoma relies on highly sensitive biochemical tests, but interpreting their results in a clinical context is a nuanced task. The probability that a positive test correctly identifies a patient with the disease—the Positive Predictive Value ($PPV$)—is critically dependent on the disease prevalence in the tested population. This practice problem [@problem_id:5170906] challenges you to apply Bayes' theorem to calculate the $PPV$ for plasma free metanephrines, providing a quantitative understanding of why a positive screening result for a rare disease is often not a definitive diagnosis and mandates further confirmatory steps.", "problem": "A tertiary referral center is evaluating patients with suspected catecholamine-secreting chromaffin tumors consistent with pheochromocytoma. Plasma free metanephrines are obtained as part of biochemical screening. In the referred population, the disease prevalence is $0.5\\%$, the test sensitivity is $97\\%$, and the test specificity is $90\\%$. Using only the definitions of sensitivity, specificity, and prevalence together with Bayes’ theorem, derive the expression for the Positive Predictive Value (PPV) defined as $P(\\text{Disease} \\mid \\text{Test positive})$, then compute its numerical value for this population. Finally, based on your computed $PPV$, state whether confirmatory testing should be pursued before surgical planning for resection and preoperative optimization with alpha-adrenergic blockade. Round your final numerical answer to four significant figures and express it as a decimal without a percent sign.", "solution": "The problem is valid as it is scientifically grounded, well-posed, and objective. It provides all necessary information to derive and compute the Positive Predictive Value (PPV) for a diagnostic test in a specified clinical context.\n\nLet $D$ be the event that a patient has the disease (pheochromocytoma), and let $T^+$ be the event that the biochemical screening test is positive. The prevalence of the disease is given as $P(D) = 0.5\\% = 0.005$. The sensitivity of the test is the probability of a positive test given the patient has the disease, which is $P(T^+ \\mid D) = 97\\% = 0.97$. The specificity of the test is the probability of a negative test given the patient does not have the disease. Let $D^c$ be the event that a patient does not have the disease. Then the specificity is $P(T^- \\mid D^c) = 90\\% = 0.90$.\n\nThe quantity to be calculated is the Positive Predictive Value (PPV), defined in the problem as $P(D \\mid T^+)$. This is the probability that a patient has the disease given that they have a positive test result.\n\nUsing the definition of conditional probability, also known as Bayes' theorem, we can express the PPV as:\n$$P(D \\mid T^+) = \\frac{P(T^+ \\mid D) P(D)}{P(T^+)}$$\n\nThe denominator, $P(T^+)$, represents the total probability of obtaining a positive test result in the given population. This can be calculated using the law of total probability, which sums the probabilities of a positive test over all possible disease states (having the disease or not having the disease):\n$$P(T^+) = P(T^+ \\mid D) P(D) + P(T^+ \\mid D^c) P(D^c)$$\n\nTo evaluate this expression, we need the values for all terms. We are given:\n- Prevalence: $P(D) = 0.005$.\n- Sensitivity: $P(T^+ \\mid D) = 0.97$.\n\nFrom these, we can derive the remaining probabilities:\n- The probability of not having the disease is $P(D^c) = 1 - P(D) = 1 - 0.005 = 0.995$.\n- The probability of a positive test in a patient without the disease, $P(T^+ \\mid D^c)$, is the complement of the specificity. Since for a given state $D^c$, the test can only be positive ($T^+$) or negative ($T^-$), the sum of their probabilities is $1$. Thus, $P(T^+ \\mid D^c) = 1 - P(T^- \\mid D^c)$. This term is also known as the false positive rate.\n$$P(T^+ \\mid D^c) = 1 - \\text{specificity} = 1 - 0.90 = 0.10$$\n\nSubstituting the expression for $P(T^+)$ into the formula for PPV, we obtain the general expression for PPV in terms of prevalence, sensitivity, and specificity:\n$$PPV = P(D \\mid T^+) = \\frac{P(T^+ \\mid D) P(D)}{P(T^+ \\mid D) P(D) + P(T^+ \\mid D^c) P(D^c)}$$\n\nNow, we substitute the numerical values into this derived expression:\n$$PPV = \\frac{(0.97) \\times (0.005)}{(0.97) \\times (0.005) + (0.10) \\times (0.995)}$$\n\nFirst, we compute the numerator:\n$$\\text{Numerator} = 0.97 \\times 0.005 = 0.00485$$\n\nNext, we compute the denominator:\n$$\\text{Denominator} = (0.97 \\times 0.005) + (0.10 \\times 0.995) = 0.00485 + 0.0995 = 0.10435$$\n\nFinally, we compute the PPV:\n$$PPV = \\frac{0.00485}{0.10435} \\approx 0.0464829904168663...$$\n\nRounding the numerical value to four significant figures as requested, we get:\n$$PPV \\approx 0.04648$$\n\nThis result means that in this population of patients referred for suspected pheochromocytoma, a positive plasma free metanephrine test indicates only a $4.648\\%$ probability that the patient actually has the disease. Conversely, the probability that a positive result is a false positive is $1 - 0.04648 = 0.95352$, or approximately $95.4\\%$.\n\nGiven the low Positive Predictive Value, a positive screening test is not sufficient to confirm the diagnosis of pheochromocytoma. Proceeding directly to surgical planning and preoperative optimization with alpha-adrenergic blockade based on this single test would be inappropriate. The risks and morbidity associated with pheochromocytoma resection are substantial, and such interventions require a high degree of diagnostic certainty. Therefore, based on the computed PPV, confirmatory testing is absolutely mandatory. This would typically involve subsequent investigations, such as 24-hour urinary fractionated metanephrines and catecholamines, and/or imaging studies like CT or MRI to anatomically localize a potential tumor, before any surgical intervention is considered.", "answer": "$$\\boxed{0.04648}$$", "id": "5170906"}, {"introduction": "Building upon the statistical realities of screening, clinicians frequently encounter borderline biochemical results that create diagnostic uncertainty. These indeterminate findings are often clouded by physiological confounders or medication interferences, making a definitive conclusion difficult. This scenario [@problem_id:5170882] immerses you in a common clinical challenge: managing a patient with a mild, isolated elevation in plasma free normetanephrine. Your task is to construct a systematic approach that mitigates false positives by standardizing testing conditions and leveraging dynamic physiological tests to distinguish true tumor secretion from sympathetic overactivity.", "problem": "A $42$-year-old with a history of unilateral adrenal pheochromocytoma (PHEO) resected $18$ months ago presents for routine follow-up. He is asymptomatic apart from labile hypertension. Current medications include venlafaxine, labetalol, and a calcium channel blocker. He has mild untreated obstructive sleep apnea. Blood was drawn for plasma free metanephrines in the seated position after minimal rest. Results show plasma free normetanephrine at $1.4 \\times$ the upper limit of normal (ULN) and plasma free metanephrine within the reference interval. Serum creatinine is normal. The previous postoperative surveillance samples were within normal limits.\n\nUse the following fundamental principles to reason the next best step:\n\n- Catecholamine-producing tumors continuously generate metanephrines via catechol-O-methyltransferase within tumor cells, whereas physiologic sympathetic activation predominantly increases norepinephrine release from nerve terminals. Therefore, plasma free metanephrines are generally more sensitive than direct catecholamines for detecting pheochromocytoma and paraganglioma (PPGL), but physiologic and analytical factors can increase false positives.\n\n- Sympathetic tone increases with upright posture, stress, and obstructive sleep apnea; supine sampling after a period of quiet rest reduces sympathetic outflow and lowers background normetanephrine, thereby improving specificity.\n\n- Certain medications, including serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors, and some beta blockers (notably labetalol), can elevate or analytically interfere with metanephrine measurements; a medication washout, when clinically safe, reduces false positives.\n\n- Clonidine is an alpha-$2$ adrenergic agonist that suppresses central sympathetic outflow. In individuals without PPGL, clonidine reduces plasma norepinephrine and normetanephrine; in PPGL, autonomous tumor production is not suppressed. The clonidine suppression test (CST) therefore helps discriminate borderline elevations due to sympathetic activation from tumor secretion, particularly for normetanephrine-predominant patterns.\n\nWhich of the following is the most appropriate next step in management of this borderline biochemical result?\n\nA. Proceed directly to cross-sectional and functional imaging from skull base to pelvis to localize recurrent disease.\n\nB. Repeat plasma free metanephrines after withholding venlafaxine and labetalol for approximately $2$ weeks if clinically safe, ensuring a standardized supine draw after $20$–$30$ minutes of rest; if plasma normetanephrine remains elevated but less than $2 \\times$ ULN, perform a clonidine suppression test.\n\nC. Switch to $24$-hour urinary catecholamines and vanillylmandelic acid only; if these are normal, conclude there is no recurrence and resume annual surveillance.\n\nD. Begin alpha-adrenergic blockade with phenoxybenzamine and schedule redo adrenalectomy given the elevated normetanephrine.\n\nE. Perform a clonidine suppression test immediately without modifying medications or sampling posture to confirm or refute recurrence expediently.", "solution": "Begin from the core physiologic and analytical principles. Plasma free metanephrines reflect continuous intratumoral metabolism; however, background sympathetic activity and assay interferences can falsely elevate results, particularly for normetanephrine. Upright posture increases sympathetic tone; a standardized supine collection after quiet rest lowers physiologic confounders. Medications such as serotonin-norepinephrine reuptake inhibitors and labetalol can elevate metanephrines or interfere with certain analytical methods; a washout, when safe, improves specificity. Clonidine, an alpha-$2$ agonist, suppresses central sympathetic outflow and should reduce plasma norepinephrine and normetanephrine in non-tumor states; failure of normetanephrine to suppress supports autonomous tumor secretion. Therefore, an evidence-based stepwise approach to borderline elevations starts by minimizing false positives through standardized sampling and medication washout; if results remain borderline, clonidine suppression is considered, especially for isolated normetanephrine elevations.\n\nAnalyze each option:\n\nA. Proceed directly to cross-sectional and functional imaging. Imaging is warranted when biochemical evidence is convincing, such as clear elevations (for example, typically at or exceeding approximately $2$–$3 \\times$ ULN) or consistent, reproducible abnormalities after confounders are addressed. Here, the normetanephrine is only $1.4 \\times$ ULN, the sample was drawn seated with minimal rest, and the patient is on venlafaxine and labetalol, both known to increase false positives. Skipping the corrective steps risks unnecessary imaging with low pretest specificity. Verdict — Incorrect.\n\nB. Repeat under standardized conditions with medication washout, then consider clonidine suppression if still borderline. This option explicitly applies the foundational principles: reduce sympathetic tone via supine draw after $20$–$30$ minutes of rest; remove known pharmacologic confounders for approximately $2$ weeks if safe; then reassess. If plasma normetanephrine remains elevated but less than $2 \\times$ ULN, moving to clonidine suppression leverages the drug’s ability to reduce central sympathetic outflow, which should lower normetanephrine in non-tumor states but not in PPGL. This stepwise plan increases specificity and appropriately reserves imaging for biochemically confirmed disease. Verdict — Correct.\n\nC. Switch to $24$-hour urinary catecholamines and vanillylmandelic acid only; if normal, conclude no recurrence. Although $24$-hour urinary metanephrines can be useful, measuring catecholamines and vanillylmandelic acid alone is less sensitive than plasma free or urinary fractionated metanephrines for PPGL. Moreover, this option neither addresses confounders (posture, rest, medications, sleep apnea) nor specifies the better-performing analytes (fractionated metanephrines). A normal urinary catecholamine/vanillylmandelic acid panel cannot reliably exclude recurrence in this context. Verdict — Incorrect.\n\nD. Begin alpha-adrenergic blockade and schedule redo adrenalectomy. Empiric alpha blockade is indicated when biochemical and clinical evidence strongly support active PPGL or when preparing for a planned resection. Here, the elevation is borderline, confounders exist, and no localization studies have been performed. Immediate operative planning would be premature and could expose the patient to unnecessary risk. Verdict — Incorrect.\n\nE. Perform a clonidine suppression test immediately without modifying medications or posture. The clonidine suppression test is most informative when baseline confounders have been minimized, because medications such as SNRIs and labetalol and seated sampling increase the likelihood of a false-positive baseline and may blunt interpretability. Proceeding directly to clonidine without standardized conditions can yield ambiguous results and is not best practice. Verdict — Incorrect.\n\nTherefore, the most appropriate next step is to repeat the test under standardized supine conditions after a medication washout and then, if still borderline ($2 \\times$ ULN) for normetanephrine, proceed to a clonidine suppression test to refine specificity before imaging or intervention.", "answer": "$$\\boxed{B}$$", "id": "5170882"}, {"introduction": "Once the diagnosis of pheochromocytoma is securely established, the critical next phase is meticulous preoperative optimization to ensure patient safety during surgery. The cornerstone of this preparation is alpha-adrenergic blockade, which controls hypertension and restores intravascular volume, mitigating the risk of life-threatening hemodynamic crises during tumor manipulation. This hands-on exercise [@problem_id:5170918] places you in the role of the managing clinician, tasked with titrating phenoxybenzamine by interpreting patient-specific data against a set of therapeutic goals and logistical constraints. Successfully navigating this problem requires integrating pharmacology, physiology, and practical clinical planning.", "problem": "A patient with biochemically confirmed pheochromocytoma is scheduled for adrenalectomy in $12$ days. Preoperative alpha-adrenergic blockade with phenoxybenzamine is planned. The fundamental hemodynamic relationship is $$MAP = CO \\times SVR,$$ where Mean Arterial Pressure (MAP) depends on Cardiac Output (CO) and Systemic Vascular Resistance (SVR). Catecholamine excess increases $SVR$, raising $MAP$. Alpha-adrenergic blockade reduces $SVR$, thereby lowering $MAP$ and blunting reflex vasoconstriction on standing. Orthostatic hypotension is defined by a fall in systolic Blood Pressure (BP) of $\\geq 20$ mmHg and/or diastolic BP of $\\geq 10$ mmHg within $3$ minutes of standing; mild orthostasis and nasal congestion are pragmatic clinical markers of adequate alpha blockade because alpha-adrenergic tone supports venous return on standing and nasal mucosal vasoconstriction at rest. \n\nYou will initiate phenoxybenzamine at $10$ mg twice daily ($20$ mg/day). Dose increases of $10$–$20$ mg/day may be made no more frequently than every $2$–$3$ days, and the patient can attend clinic on days $3$, $6$, and $9$ for dose reassessment. Because phenoxybenzamine produces irreversible receptor blockade with downstream physiologic equilibration requiring volume repletion, hemodynamic evaluation should occur after at least $48$–$72$ hours at a stable dose to ensure steady effect.\n\nEmpiric dose-response data for this patient, measured after stabilization at each dose, are as follows:\n- At $20$ mg/day: supine BP $150/95$ mmHg, standing BP $140/90$ mmHg, nasal congestion absent.\n- At $40$ mg/day: supine BP $140/92$ mmHg, standing BP $120/86$ mmHg, nasal congestion minimal.\n- At $50$ mg/day: supine BP $130/88$ mmHg, standing BP $105/80$ mmHg, nasal congestion present.\n- At $60$ mg/day: supine BP $118/82$ mmHg, standing BP $85/70$ mmHg, nasal congestion significant.\n\nThe target for adequate preoperative alpha blockade is defined for this problem as mild orthostasis with standing systolic BP between $90$ and $110$ mmHg, an orthostatic systolic drop of $\\geq 20$ mmHg, and nasal congestion present, without symptoms of severe hypotension. \n\nWhich titration schedule best satisfies the dosing constraints, uses clinic reassessment days of $3$, $6$, and $9$, respects the $48$–$72$ hour stabilization requirement before deciding on adequacy, and achieves the target as early as possible without overshooting?\n\nA. Day $0$: $20$ mg/day. Day $2$: increase to $40$ mg/day. Day $4$: increase to $60$ mg/day. Declare target achieved on day $4$ and maintain $60$ mg/day to surgery.\n\nB. Day $0$: $20$ mg/day. Day $3$: increase to $40$ mg/day. Day $6$: increase to $50$ mg/day. Day $8$: evaluate after $48$ hours at $50$ mg/day; target achieved; maintain $50$ mg/day to surgery.\n\nC. Day $0$: $20$ mg/day. Day $3$: increase to $30$ mg/day. Day $6$: increase to $40$ mg/day. Day $9$: increase to $50$ mg/day. Day $11$: evaluate after $48$ hours at $50$ mg/day; target achieved; maintain $50$ mg/day to surgery.\n\nD. Day $0$: $20$ mg/day. Day $3$: increase to $40$ mg/day. Day $6$: increase to $60$ mg/day. Day $9$: evaluate after $72$ hours at $60$ mg/day; target achieved; maintain $60$ mg/day to surgery.\n\nE. Day $0$: $20$ mg/day. Day $3$: increase to $30$ mg/day. Day $6$: increase to $50$ mg/day. Declare target achieved on day $6$ and maintain $50$ mg/day to surgery.", "solution": "### Problem Validation\n\nThis is a clinical optimization problem grounded in pharmacology and physiology. The validation will proceed by first extracting the givens and then evaluating them against the criteria of scientific soundness, objectivity, and completeness.\n\n#### Step 1: Extract Givens\n\n1.  **Scheduled Procedure:** Adrenalectomy in $12$ days for biochemically confirmed pheochromocytoma.\n2.  **Preoperative Medication:** Phenoxybenzamine for alpha-adrenergic blockade.\n3.  **Fundamental Physiology:** $MAP = CO \\times SVR$. Catecholamine excess increases $SVR$ and $MAP$. Alpha-blockade reduces $SVR$ and $MAP$.\n4.  **Clinical Signs of Blockade:** Orthostatic hypotension and nasal congestion.\n5.  **Definition of Orthostatic Hypotension:** Fall in systolic BP $\\geq 20$ mmHg and/or diastolic BP $\\geq 10$ mmHg within $3$ minutes of standing.\n6.  **Titration Protocol:**\n    *   **Starting Dose:** $10$ mg twice daily ($20$ mg/day), initiated on Day $0$.\n    *   **Dose Increases:** Increments of $10$–$20$ mg/day.\n    *   **Frequency of Increase:** No more frequently than every $2$–$3$ days.\n    *   **Reassessment Schedule:** Clinic visits on Day $3$, Day $6$, and Day $9$. Dose adjustments occur on these days.\n    *   **Stabilization Period:** Hemodynamic evaluation must occur after at least $48$–$72$ hours at a stable dose.\n7.  **Empiric Dose-Response Data:**\n    *   $20$ mg/day: Supine BP $150/95$ mmHg, Standing BP $140/90$ mmHg.\n    *   $40$ mg/day: Supine BP $140/92$ mmHg, Standing BP $120/86$ mmHg.\n    *   $50$ mg/day: Supine BP $130/88$ mmHg, Standing BP $105/80$ mmHg.\n    *   $60$ mg/day: Supine BP $118/82$ mmHg, Standing BP $85/70$ mmHg.\n8.  **Target for Adequate Blockade:**\n    *   Standing systolic BP between $90$ mmHg and $110$ mmHg.\n    *   Orthostatic systolic drop $\\geq 20$ mmHg.\n    *   Nasal congestion present.\n    *   Absence of symptoms of severe hypotension.\n9.  **Optimization Goal:** Find the titration schedule that satisfies all constraints, uses the specified clinic days, respects stabilization time, and achieves the target as early as possible without overshooting.\n\n#### Step 2: Validate Using Extracted Givens\n\n*   **Scientifically Grounded:** The problem is firmly based on established principles of cardiovascular physiology ($MAP = CO \\times SVR$) and pharmacology (the mechanism of action and clinical effects of phenoxybenzamine in managing pheochromocytoma). The definitions and values provided are medically and scientifically accurate.\n*   **Well-Posed:** The problem provides a clear set of initial conditions, constraints, empirical data, and a well-defined target. The objective function (achieve target \"as early as possible\") makes it an optimization problem for which a unique best solution among the options can be identified.\n*   **Objective:** The problem uses precise, quantitative definitions for orthostasis and the therapeutic target. The dose-response data is provided as an empirical fact for this specific case. The language is objective and free of subjective claims.\n\nThe problem statement is internally consistent, scientifically sound, and well-posed. There are no violations of the validation criteria.\n\n#### Step 3: Verdict and Action\n\nThe problem statement is **valid**. Proceeding to the solution.\n\n### Solution Derivation\n\nThe goal is to find the optimal titration schedule to achieve a specific hemodynamic state. First, we must identify which dose level meets the target criteria.\n\n**Analysis of Dose-Response Data:**\nThe target is defined by three conditions:\n1.  Standing Systolic BP (SBP): $90 \\leq \\text{SBP}_{\\text{standing}} \\leq 110$ mmHg.\n2.  Orthostatic Systolic Drop: $\\text{SBP}_{\\text{supine}} - \\text{SBP}_{\\text{standing}} \\geq 20$ mmHg.\n3.  Side Effect: Nasal congestion must be \"present\".\n\nLet's evaluate each dose from the provided data:\n*   **$20$ mg/day:**\n    *   Standing SBP = $140$ mmHg (outside $[90, 110]$).\n    *   Systolic drop = $150 - 140 = 10$ mmHg ($ 20$ mmHg).\n    *   Nasal congestion: absent.\n    *   **Conclusion: Target not met.**\n*   **$40$ mg/day:**\n    *   Standing SBP = $120$ mmHg (outside $[90, 110]$).\n    *   Systolic drop = $140 - 120 = 20$ mmHg ($\\geq 20$ mmHg).\n    *   Nasal congestion: minimal (may not satisfy \"present\").\n    *   **Conclusion: Target not met.**\n*   **$50$ mg/day:**\n    *   Standing SBP = $105$ mmHg (within $[90, 110]$).\n    *   Systolic drop = $130 - 105 = 25$ mmHg ($\\geq 20$ mmHg).\n    *   Nasal congestion: present.\n    *   **Conclusion: Target is met.**\n*   **$60$ mg/day:**\n    *   Standing SBP = $85$ mmHg (outside $[90, 110]$; this is an overshoot).\n    *   Systolic drop = $118 - 85 = 33$ mmHg ($\\geq 20$ mmHg).\n    *   Nasal congestion: significant.\n    *   **Conclusion: Target is overshot.**\n\nThe optimal dose is therefore $50$ mg/day. The problem reduces to finding the fastest valid schedule to reach and confirm stabilization at $50$ mg/day.\n\n**Analysis of Titration Schedules:**\nConstraints to check for each option:\n*   Titration occurs only on clinic days (Day $3$, $6$, $9$).\n*   Dose increments are between $10$ mg/day and $20$ mg/day.\n*   Dose changes are at least $2$–$3$ days apart (guaranteed by clinic schedule).\n*   Evaluation of target achievement occurs only after $48$–$72$ hours on the final dose.\n*   The final dose must be the target dose ($50$ mg/day).\n\n### Option-by-Option Analysis\n\n**A. Day $0$: $20$ mg/day. Day $2$: increase to $40$ mg/day. Day $4$: increase to $60$ mg/day. Declare target achieved on day $4$ and maintain $60$ mg/day to surgery.**\n*   This schedule violates the constraint that dose reassessment and changes occur on clinic days ($3$, $6$, $9$). Changes are made on days $2$ and $4$.\n*   It incorrectly selects a dose of $60$ mg/day, which overshoots the target.\n*   It violates the stabilization rule by declaring the target achieved on Day $4$, the same day the dose was increased. An evaluation requires waiting at least $48$ hours.\n*   **Verdict: Incorrect.**\n\n**B. Day $0$: $20$ mg/day. Day $3$: increase to $40$ mg/day. Day $6$: increase to $50$ mg/day. Day $8$: evaluate after $48$ hours at $50$ mg/day; target achieved; maintain $50$ mg/day to surgery.**\n*   **Day $0$: Start $20$ mg/day.** Correct.\n*   **Day $3$: Increase to $40$ mg/day.** This is a clinic day. The increase is $20$ mg/day, which is within the allowed range [$10, 20$]. The interval is $3$ days. All rules are satisfied.\n*   **Day $6$: Increase to $50$ mg/day.** This is a clinic day. The increase is $10$ mg/day, which is within the allowed range. The interval is $3$ days. All rules are satisfied. The patient is now on the target dose.\n*   **Day $8$: Evaluate.** Day $8$ is $48$ hours after the dose change on Day $6$. This respects the $48$–$72$ hour stabilization requirement. At $50$ mg/day, the target is achieved. This schedule reaches the target and confirms it at the earliest possible time given the constraints.\n*   **Verdict: Correct.**\n\n**C. Day $0$: $20$ mg/day. Day $3$: increase to $30$ mg/day. Day $6$: increase to $40$ mg/day. Day $9$: increase to $50$ mg/day. Day $11$: evaluate after $48$ hours at $50$ mg/day; target achieved; maintain $50$ mg/day to surgery.**\n*   This schedule follows all rules regarding clinic days, dose increments, and stabilization time.\n*   However, it employs a less aggressive titration. The target dose of $50$ mg/day is not started until Day $9$, with confirmation on Day $11$.\n*   Schedule B starts the target dose on Day $6$ with confirmation on Day $8$.\n*   Since the goal is to achieve the target \"as early as possible,\" this schedule is suboptimal compared to schedule B.\n*   **Verdict: Incorrect.**\n\n**D. Day $0$: $20$ mg/day. Day $3$: increase to $40$ mg/day. Day $6$: increase to $60$ mg/day. Day $9$: evaluate after $72$ hours at $60$ mg/day; target achieved; maintain $60$ mg/day to surgery.**\n*   The titration schedule itself is valid up to the dose selection.\n*   The fatal flaw is the choice of the final dose. On Day $6$, the dose is increased to $60$ mg/day. As determined from the data, this dose overshoots the target, with standing systolic BP falling to $85$ mmHg. The statement \"target achieved\" is false.\n*   **Verdict: Incorrect.**\n\n**E. Day $0$: $20$ mg/day. Day $3$: increase to $30$ mg/day. Day $6$: increase to $50$ mg/day. Declare target achieved on day $6$ and maintain $50$ mg/day to surgery.**\n*   The titration schedule (dose increases on clinic days) is valid.\n*   The fatal flaw is the evaluation timing. It declares the target achieved on Day $6$, the same day the dose was increased to $50$ mg/day. This violates the mandatory $48$–$72$ hour stabilization period before evaluation.\n*   **Verdict: Incorrect.**", "answer": "$$\\boxed{B}$$", "id": "5170918"}]}